Why does it take so long to diagnose such a treatable condition?
June is Myasthenia Gravis Awareness Month, and for a condition that quietly affects up to 100,000 Americans, it doesn't get nearly enough attention. Myasthenia gravis (MG) is a chronic autoimmune disease in which the immune system produces antibodies that block communication between nerves and muscles. The result is fluctuating weakness that can affect the ability to see clearly, swallow, speak, smile, walk, or breathe. Despite how significantly MG disrupts daily life, many patients wait months or even years before receiving a correct diagnosis.
MG can affect anyone at any age, regardless of race or gender. It is most common in women under 40 and men over 60. Worldwide, an estimated 20 people per 100,000 are living with the condition. In roughly half of all cases, the first symptom is eyelid drooping or double vision. From there, symptoms tend to worsen over time, often reaching their most severe point within the first few years after diagnosis. In a small number of cases, it affects breathing muscles, which is a life-threatening complication known as a myasthenic crisis.
The last decade has brought real momentum in MG treatment. For years, the main options were cholinesterase inhibitors, corticosteroids, and immunosuppressants, which have significant side effects and left many patients still struggling with symptoms. However, more recently, several new targeted therapies have now been approved, including complement inhibitors (like eculizumab) and neonatal Fc receptor (FcRn) blockers (like efgartigimod and rozanolixizumab), which work by reducing the harmful antibodies driving MG. In late 2025, the FDA also approved inebilizumab (Uplizna), which may offer long-term disease control with just two doses a year after an initial loading period.
Yet, even as the science on treatments is improving, patients still face significant diagnostic challenges. Because MG is rare, it is often overlooked by physicians. Moreover, its symptoms fluctuate and overlap with more common conditions, and the antibody tests used to confirm it can take months or years to return a positive result. The delay in diagnosis can exceed 3 years. The recent breakthroughs in treatment have brought more awareness of MG to the general public, but there is still much to be done. There needs to be more outreach to neurologists, primary care providers, and other healthcare professionals like ophthalmologists, so that the people who treat patients and can make the initial diagnosis are more aware of the condition.
MG is not alone in this diagnostic gap. Across autoimmune diseases, from lupus to multiple sclerosis, patients routinely wait years before receiving an accurate diagnosis, often cycling through specialists and incorrect treatments in the meantime. The expansion of targeted therapies is a meaningful step forward. But better treatments only help patients who have been correctly diagnosed. Closing the gap between symptom onset and diagnosis remains one of the most urgent and most overlooked challenges in autoimmune care.
If you have MG, or any autoimmune disease, consider adding your experience to our registry. Our disease-specific diagnostic surveys collect important data like time to diagnosis, the specialists patients are referred to, and the lab tests that result in a diagnosis. The data you contribute can help researchers identify patterns, track outcomes, and accelerate the path to quicker diagnosis and better treatments. Share this with someone you know who has MG or other autoimmune diseases.
To support the Autoimmune Registry, please share our information with others who have autoimmune diseases. Donations are also greatly appreciated!
Check out our previous newsletters:
